• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

Acyclovir L-Isoleucinate: A Novel Prodrug for Enhanced Antiviral Therapy

Acyclovir L-Isoleucinate, a prodrug derivative of the well-known antiviral agent Acyclovir, represents a significant advancement in the field of pharmaceutical chemistry. This compound, identified by the CAS number 142963-63-1, has garnered considerable attention due to its potential to improve the efficacy and bioavailability of Acyclovir while minimizing associated side effects. The introduction of L-Isoleucine as a carrier molecule in this prodrug formulation leverages the unique metabolic properties of this amino acid, enhancing the overall therapeutic profile of Acyclovir.

The development of Acyclovir L-Isoleucinate is driven by the need for more efficient and targeted antiviral treatments. Traditional formulations of Acyclovir, while effective, often suffer from poor oral bioavailability and rapid metabolism, limiting their clinical utility. By incorporating L-Isoleucine, a naturally occurring amino acid, into the molecular structure of Acyclovir, researchers have created a prodrug that exhibits improved pharmacokinetic properties. This modification allows for slower degradation and more sustained release of active Acyclovir within the body, thereby increasing its therapeutic window.

Recent studies have highlighted the promising applications of Acyclovir L-Isoleucinate in treating viral infections. One notable area of research focuses on its potential use in managing Herpes Simplex Virus (HSV) infections. Traditional Acyclovir therapy often requires frequent dosing due to its short half-life, which can lead to patient non-compliance and increased healthcare costs. In contrast, Acyclovir L-Isoleucinate demonstrates a longer half-life, allowing for less frequent dosing while maintaining therapeutic levels of the active drug. This improvement could significantly enhance patient adherence and overall treatment outcomes.

Furthermore, the structural modification introduced by L-Isoleucine may contribute to reduced toxicity associated with Acyclovir therapy. Preliminary in vitro studies suggest that Acyclovir L-Isoleucinate exhibits lower cytotoxicity compared to its parent compound, making it a potentially safer option for long-term treatment regimens. This finding is particularly relevant for immunocompromised patients who often require prolonged antiviral therapy to prevent recurrent infections.

The pharmacokinetic advantages of Acyclovir L-Isoleucinate have also been explored in preclinical models. Animal studies indicate that this prodrug exhibits superior absorption and distribution profiles compared to standard Acyclovir formulations. The enhanced permeability and retention (EPR) effect associated with L-Isoleucine may allow for targeted delivery to infected tissues, further optimizing therapeutic efficacy. These findings are supported by recent research demonstrating improved viral load reduction in animal models infected with HSV when treated with Acyclovir L-Isoleucinate.

From a chemical perspective, the synthesis of Acyclovir L-Isoleucinate involves a carefully orchestrated reaction sequence that ensures high yield and purity. The process typically involves esterification or amide bond formation between Acyclovir and L-Isoleucine under controlled conditions. Advances in synthetic methodologies have enabled the production of this prodrug with minimal impurities, ensuring its suitability for clinical applications. The use of chiral resolution techniques has also been critical in obtaining the enantiomerically pure form of Acyclovir L-Isoleucinate, which is essential for maintaining its pharmacological integrity.

The clinical potential of Acyclovir L-Isoleucinate extends beyond HSV infections. Emerging research suggests that this prodrug may be effective against other viral pathogens, including Varicella-Zoster Virus (VZV) and even certain strains of Cytomegalovirus (CMV). The broad-spectrum antiviral activity observed in preliminary trials underscores the versatility of this approach in developing novel therapeutic strategies against diverse viral infections.

Regulatory considerations play a crucial role in the advancement of Acyclovir L-Isoleucinate towards clinical approval. Manufacturers must adhere to stringent guidelines set forth by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to ensure safety and efficacy. Clinical trials are currently underway to evaluate the safety profile and therapeutic benefits of this prodrug in human subjects. Positive results from these trials could pave the way for its approval as an alternative or adjunctive therapy for various viral infections.

The economic implications of introducing Acyclovir L-Isoleucinate into clinical practice are also noteworthy. By improving treatment efficacy and reducing side effects, this prodrug has the potential to lower healthcare costs associated with prolonged therapy and hospitalizations. Additionally, if proven effective against multiple viral pathogens, it could reduce the need for multiple medications, simplifying treatment regimens for patients.

Future research directions for Acyclovir L-Isoleucinate include exploring combination therapies with other antiviral agents to enhance efficacy against drug-resistant strains. Additionally, investigating novel delivery systems such as nanoparticles or liposomes could further improve bioavailability and targeted delivery. These advancements would contribute to a more comprehensive arsenal against viral infections.

In conclusion, Acyclovir L-Isoleucinate represents a significant innovation in antiviral therapy due to its improved pharmacokinetic properties and reduced toxicity compared to traditional formulations of Acyclovir. The incorporation of L-Isoleucine as a carrier molecule enhances bioavailability and therapeutic efficacy while minimizing side effects. Ongoing research continues to uncover its potential applications in treating various viral infections, making it a promising candidate for future clinical use.

• 1356019-51-6(Bis Valacyclovir (~90%))
• 142963-60-8(D-Valine,2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester)
• 847670-62-6(N-Formyl Valacyclovir)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)